Dataset Information


Valproic acid, an inhibitor of class I histone deacetylases, reverses acquired Erlotinib-resistance of lung adenocarcinoma cells: a Connectivity Mapping analysis and an experimental study.

ABSTRACT: Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKI) have been used as a powerful targeting therapeutic agent for treatment of lung adenocarcinoma for years. Nevertheless, the efficacy of TKI was hampered by the appearance of acquired TKI-resistance. In the present study, we aimed to search, predict, and screen the agents that can overcome the acquired TKI-resistance of lung adenocarcinoma by using the expression profiles of differentially expressed genes (DEGs) and Connectivity map (CMAP). The profiles of DEGs were obtained by searching GEO microarray database, and then, they were submitted to CMAP for analysis in order to predict and screen the agent that might reverse the TKI-resistance of lung cancer cells. Next, the effects of the selected agent on TKI-resistant cancer cells were tested and the possible signaling pathways were also evaluated. As a result, valproic acid (VPA) was selected. Then, we used a low-concentration of VPA that has little effect on the cell growth for analysis. Interestingly, the results showed that treatment with a combination of VPA and Erlotinib significantly led to a decrease in cell viability and an increase in cell apoptosis for TKI-resistant HCC827-ER cells, relative to those treated with VPA or Erlotinib alone. Further experiments confirmed that inhibition of MAPK and AKT might be involved in this process. Analyzing the DEGs through the CMAP is a good strategy for exploitation of anti-tumor agents. VPA might markedly increase the sensitivity of TKI-resistant lung adenocarcinoma cells to Erlotinib, thus reversing the acquired TKI-resistance of cancer cells and raising VPA as a potential agent for TKI-resistant lung cancer therapy.


PROVIDER: S-EPMC4548331 | BioStudies | 2015-01-01

REPOSITORIES: biostudies

Similar Datasets

2016-01-01 | S-EPMC4715986 | BioStudies
1000-01-01 | S-EPMC4808021 | BioStudies
2015-01-01 | S-EPMC6461560 | BioStudies
2016-01-01 | S-EPMC4715957 | BioStudies
2019-01-01 | S-EPMC6889213 | BioStudies
2013-01-01 | S-EPMC3817236 | BioStudies
2015-01-30 | PXD001101 | Pride
1000-01-01 | S-EPMC4236614 | BioStudies
2017-01-01 | S-EPMC5530116 | BioStudies
2020-01-01 | S-EPMC7498675 | BioStudies